drugset
drugset / Trial / NCT04008992

An Ascending Dose Study of BMS-986259 to Study Safety in Healthy Participants

NCT04008992 ↗

Phase 1 Completed 132 enrolled Bristol-Myers Squibb
RandomizedSequentialDouble-blindPrevention

Summary

A Randomized double blind, placebo controlled study of BMS-986259 to evaluate the safety and effectiveness of the drug amongst different conditions and populations.

Timeline

Start
2019-06-18
Primary completion
2021-01-04
Completion
2021-01-04

Drugs

EvaluationDrugModalityDoseRoute
Subject BMS-986259 Unknown — —

Indications

No indication recorded.